Crinetics Pharmaceuticals, Inc. CRNX
- PALSONIFY — Acromegaly Approved
- PALSONIFY — Carcinoid Syndrome Phase 3
- CRN09682 — Neuroendocrine Tumors Phase 1
SST2 (1 companies · 3 programs)
Companies with an active program directed at SST2.
Companies with an active program directed at SST2.